Literature DB >> 28696256

A Novel Subset of Anti-Inflammatory CD138+ Macrophages Is Deficient in Mice with Experimental Lupus.

Shuhong Han1, Haoyang Zhuang1, Stepan Shumyak1, Jingfan Wu1, Hui Li2, Li-Jun Yang2, Westley H Reeves3.   

Abstract

Dead cells accumulating in the tissues may contribute to chronic inflammation. We examined the cause of impaired apoptotic cell clearance in human and murine lupus. Dead cells accumulated in bone marrow from lupus patients but not from nonautoimmune patients undergoing myeloablation, where they were efficiently removed by macrophages (MΦ). Impaired apoptotic cell uptake by MΦ also was seen in mice treated i.p. with pristane (develop lupus) but not mineral oil (MO) (do not develop lupus). The inflammatory response to both pristane and MO rapidly depleted resident (Tim4+) large peritoneal MΦ. The peritoneal exudate of pristane-treated mice contained mainly Ly6Chi inflammatory monocytes; whereas in MO-treated mice, it consisted predominantly of a novel subset of highly phagocytic MΦ resembling small peritoneal MΦ (SPM) that expressed CD138+ and the scavenger receptor Marco. Treatment with anti-Marco-neutralizing Abs and the class A scavenger receptor antagonist polyinosinic acid inhibited phagocytosis of apoptotic cells by CD138+ MΦ. CD138+ MΦ expressed IL-10R, CD206, and CCR2 but little TNF-α or CX3CR1. They also expressed high levels of activated CREB, a transcription factor implicated in generating alternatively activated MΦ. Similar cells were identified in the spleen and lung of MO-treated mice and also were induced by LPS. We conclude that highly phagocytic, CD138+ SPM-like cells with an anti-inflammatory phenotype may promote the resolution of inflammation in lupus and infectious diseases. These SPM-like cells are not restricted to the peritoneum and may help clear apoptotic cells from tissues such as the lung, helping to prevent chronic inflammation.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28696256      PMCID: PMC5548631          DOI: 10.4049/jimmunol.1700099

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  71 in total

Review 1.  Resolution of inflammation: the beginning programs the end.

Authors:  Charles N Serhan; John Savill
Journal:  Nat Immunol       Date:  2005-12       Impact factor: 25.606

2.  A murine scavenger receptor MARCO recognizes polystyrene nanoparticles.

Authors:  Sanae Kanno; Akiko Furuyama; Seishiro Hirano
Journal:  Toxicol Sci       Date:  2007-03-14       Impact factor: 4.849

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction.

Authors:  Gaetano Zizzo; Brendan A Hilliard; Marc Monestier; Philip L Cohen
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

5.  Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.

Authors:  Simon Yona; Ki-Wook Kim; Yochai Wolf; Alexander Mildner; Diana Varol; Michal Breker; Dalit Strauss-Ayali; Sergey Viukov; Martin Guilliams; Alexander Misharin; David A Hume; Harris Perlman; Bernard Malissen; Elazar Zelzer; Steffen Jung
Journal:  Immunity       Date:  2012-12-27       Impact factor: 31.745

Review 6.  Acute myeloid leukaemia: optimal management and recent developments.

Authors:  Luis Villela; Javier Bolaños-Meade
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

7.  Glomerular cell apoptosis in human lupus nephritis.

Authors:  Hirofumi Makino; Hitoshi Sugiyama; Yasushi Yamasaki; Yohei Maeshima; Jun Wada; Naoki Kashihara
Journal:  Virchows Arch       Date:  2003-05-15       Impact factor: 4.064

8.  CREB pathway links PGE2 signaling with macrophage polarization.

Authors:  Bing Luan; Young-Sil Yoon; John Le Lay; Klaus H Kaestner; Susan Hedrick; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

9.  Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.

Authors:  Aieska De Souza; Bruce E Strober; Joseph F Merola; Stephen Oliver; Andrew G Franks
Journal:  J Drugs Dermatol       Date:  2012-10       Impact factor: 2.114

Review 10.  Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2015-10-06
View more
  11 in total

1.  NF-E2-Related Factor 2 Regulates Interferon Receptor Expression and Alters Macrophage Polarization in Lupus.

Authors:  Shuhong Han; Haoyang Zhuang; Pui Y Lee; Mingjia Li; Lijun Yang; Peter A Nigrovic; Westley H Reeves
Journal:  Arthritis Rheumatol       Date:  2020-08-09       Impact factor: 10.995

Review 2.  Common innate pathways to autoimmune disease.

Authors:  David Langan; Noel R Rose; Kamal D Moudgil
Journal:  Clin Immunol       Date:  2020-02-10       Impact factor: 3.969

3.  Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon.

Authors:  Shuhong Han; Haoyang Zhuang; Pui Y Lee; Mingjia Li; Lijun Yang; Peter A Nigrovic; Westley H Reeves
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 10.995

4.  A novel monocyte differentiation pattern in pristane-induced lupus with diffuse alveolar hemorrhage.

Authors:  Shuhong Han; Haoyang Zhuang; Rawad Daniel Arja; Westley H Reeves
Journal:  Elife       Date:  2022-10-20       Impact factor: 8.713

5.  Regulation of Leukocyte Recruitment to the Spleen and Peritoneal Cavity during Pristane-Induced Inflammation.

Authors:  Yu Li; Junping Wu; Long Xu; Qi Wu; Zhen Wan; Li Li; Hongzhi Yu; Xue Li; Kuan Li; Qiuyang Zhang; Zhili Hou; Xin Sun; Huaiyong Chen
Journal:  J Immunol Res       Date:  2017-10-19       Impact factor: 4.818

6.  Rubicon promotes rather than restricts murine lupus and is not required for LC3-associated phagocytosis.

Authors:  Rachael A Gordon; Christina Giannouli; Chirag Raparia; Sheldon I Bastacky; Anthony Marinov; William Hawse; Richard Cattley; Jeremy S Tilstra; Allison M Campbell; Kevin M Nickerson; Anne Davidson; Mark J Shlomchik
Journal:  JCI Insight       Date:  2022-04-08

7.  Liver X Receptor Agonist Therapy Prevents Diffuse Alveolar Hemorrhage in Murine Lupus by Repolarizing Macrophages.

Authors:  Shuhong Han; Haoyang Zhuang; Stepan Shumyak; Jingfan Wu; Chao Xie; Hui Li; Li-Jun Yang; Westley H Reeves
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

8.  IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation.

Authors:  Senthil Kumaran Satyanarayanan; Driss El Kebir; Soaad Soboh; Sergei Butenko; Meriem Sekheri; Janan Saadi; Neta Peled; Simaan Assi; Amira Othman; Sagie Schif-Zuck; Yonatan Feuermann; Dalit Barkan; Noa Sher; János G Filep; Amiram Ariel
Journal:  Nat Commun       Date:  2019-08-02       Impact factor: 14.919

9.  Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus.

Authors:  Leila Abdelhamid; Xavier Cabana-Puig; Brianna Swartwout; Jiyoung Lee; Song Li; Sha Sun; Yaqi Li; A Catharine Ross; Thomas E Cecere; Tanya LeRoith; Stephen R Werre; Haifeng Wang; Christopher M Reilly; Xin M Luo
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

10.  Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study.

Authors:  Maria Tió-Coma; Anouk van Hooij; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Sayera Banu; Saraswoti Khadge; Pratibha Thapa; Chhatra B Kunwar; Isabela M Goulart; Yonas Bekele; Deanna A Hagge; Milton O Moraes; Rosane M B Teles; Roberta Olmo Pinheiro; Erik W van Zwet; Jelle J Goeman; Abraham Aseffa; Mariëlle C Haks; Tom H M Ottenhoff; Robert L Modlin; Annemieke Geluk
Journal:  Sci Rep       Date:  2019-11-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.